Cancer Family
Digestive System Neoplasm
CI-CAN-00000012Explore in graph →
Non-malignant4,733 active trials43 approved drugs557 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000012Explore in graph →
Clinical trials
22,059 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05440708 | A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma | recruiting | Phase 1 / Phase 2 | 193 | Tvardi Therapeutics, IncorporatedINDUSTRY | 1 | Apr 27, 2026 | clinicaltrials |
| NCT06723236 | A Study of MGC028 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 124 | MacroGenicsINDUSTRY | 1 | Apr 27, 2026 | clinicaltrials |
| NCT07453875 | LDRT Sequential NIPS Immunochemotherapy for Peritoneal Metastasis of Gastric and Colorectal Cancer(TRIUNITE06) | not yet recruiting | Phase 1 | 9 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT07551362 | Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer(DUET-GEJ) | recruiting | Phase 1 / Phase 2 | 36 | Beijing BiotechINDUSTRY | 1 | Apr 24, 2026 | clinicaltrials |
| NCT00669734 | Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery | active not recruiting | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06483555 | Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel(PANGEA) | recruiting | Phase 1 / Phase 2 | 104 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06720987 | A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies | recruiting | Phase 1 | 140 | Kumquat Biosciences Inc.INDUSTRY | 1 | Apr 23, 2026 | clinicaltrials |
| NCT07020221 | A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors | recruiting | Phase 1 / Phase 2 | 295 | Verastem, Inc.INDUSTRY | 2 | Apr 22, 2026 | clinicaltrials |
| NCT07542704 | A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies | not yet recruiting | Phase 1 | 48 | Kumquat Biosciences Inc.INDUSTRY | 0 | Apr 21, 2026 | clinicaltrials |
| NCT02174549 | Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer | recruiting | Phase 1 / Phase 2 | 25 | Teclison Ltd.INDUSTRY | 1 | Apr 20, 2026 | clinicaltrials |
| NCT04605731 | Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer | active not recruiting | Phase 1 | 25 | City of Hope Medical CenterOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07488312 | Safety and Efficacy of Leucine-Restricted Diet in Gastric Cancer(LUCENT-GC-01) | enrolling by invitation | Phase 1 | 37 | Qilu Hospital of Shandong UniversityOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT04725994 | Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer | active not recruiting | Phase 1 / Phase 2 | 87 | Idience Co., Ltd.INDUSTRY | 3 | Apr 17, 2026 | clinicaltrials |
| NCT06777316 | A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 110 | Cogent Biosciences, Inc.INDUSTRY | 2 | Apr 17, 2026 | clinicaltrials |
| NCT06833866 | Phase I Trial of 5-Fluorouracil (5FU) -Based Therapy in Combination With Hydroxytyrosol (HT) in Patients With Advanced or Metastatic Colorectal Cancer | recruiting | Phase 1 | 33 | The Methodist Hospital Research InstituteOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT03157128 | A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)(LIBRETTO-001) | active not recruiting | Phase 1 / Phase 2 | 857 | Eli Lilly and CompanyINDUSTRY | 16 | Apr 16, 2026 | clinicaltrials |
| NCT05842174 | Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma(TAQE) | recruiting | Phase 1 / Phase 2 | 93 | VA Office of Research and DevelopmentFED | 1 | Apr 16, 2026 | clinicaltrials |
| NCT06708663 | HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 124 | Hangzhou Hanx Biopharmaceuticals, Ltd.INDUSTRY | 1 | Apr 16, 2026 | clinicaltrials |
| NCT04220827 | Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer | active not recruiting | Phase 1 | 27 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT04308330 | Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies(NYMC195) | recruiting | Phase 1 | 30 | New York Medical CollegeOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06799637 | Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments | recruiting | Phase 1 / Phase 2 | 350 | Evopoint Biosciences Inc.INDUSTRY | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07353645 | KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 49 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05257993 | Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 71 | Onconic Therapeutics Inc.INDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06362369 | A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy | recruiting | Phase 1 / Phase 2 | 126 | 7 Hills Pharma, LLCINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06454383 | Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer | recruiting | Phase 1 | 19 | City of Hope Medical CenterOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07114861 | The KN510713 Study in Combination With mFOLFIRINOX | recruiting | Phase 1 / Phase 2 | 30 | New Cancer Cure-Bio Co.,Ltd.INDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07522411 | Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 100 | BinYong LiangOTHER | 0 | Apr 13, 2026 | clinicaltrials |
| NCT05048901 | Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors | recruiting | Phase 1 / Phase 2 | 49 | National Health Research Institutes, TaiwanOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT05927857 | Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer . | recruiting | Phase 1 / Phase 2 | 45 | National Health Research Institutes, TaiwanOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT06431490 | A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer | recruiting | Phase 1 / Phase 2 | 102 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 8, 2026 | clinicaltrials |
| NCT04906434 | A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor | recruiting | Phase 1 | 200 | Abbisko Therapeutics Co, LtdINDUSTRY | 3 | Apr 7, 2026 | clinicaltrials |
| NCT05003895 | GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies | recruiting | Phase 1 | 38 | National Cancer Institute (NCI)NIH | 1 | Apr 7, 2026 | clinicaltrials |
| NCT06639724 | Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer | recruiting | Phase 1 | 36 | University of California, San DiegoOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT06848465 | LDRT Combined With Immunochemotherapy for Colorectal Cancer With Liver Metastasis | recruiting | Phase 1 | 9 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT07107750 | Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer | recruiting | Phase 1 | 48 | Washington University School of MedicineOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT06451497 | This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 100 | Zumutor Biologics Inc.INDUSTRY | 1 | Apr 2, 2026 | clinicaltrials |
| NCT06654297 | Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinomas | active not recruiting | Phase 1 | 6 | West China HospitalOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT07504523 | Personalized T-Cell Therapy iNeo-Vac-T01 in Advanced Colorectal Cancer | recruiting | Phase 1 | 20 | Ying Yuan, MDOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT07504263 | Phase 1/2a Study of RP-001 in Participants With Advanced Malignancies | not yet recruiting | Phase 1 / Phase 2 | 66 | Recurv Pharma IncINDUSTRY | 0 | Mar 31, 2026 | clinicaltrials |
| NCT03860272 | Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer | active not recruiting | Phase 1 | 499 | Agenus Inc.INDUSTRY | 2 | Mar 30, 2026 | clinicaltrials |
| NCT04703101 | Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer | recruiting | Phase 1 | 25 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT05984602 | A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer | active not recruiting | Phase 1 | 9 | NYU Langone HealthOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07500220 | Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC(DUET-HCC) | recruiting | Phase 1 / Phase 2 | 30 | Beijing BiotechINDUSTRY | 1 | Mar 30, 2026 | clinicaltrials |
| NCT06395519 | A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies(ERADIC8) | recruiting | Phase 1 / Phase 2 | 120 | 858 Therapeutics, Inc.INDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06687941 | A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients With GPC3-positive Advanced Solid Tumors | recruiting | Phase 1 | 70 | Aptamer Sciences, Inc.INDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07495215 | A Clinical Study on the Safety, Tolerability and Efficacy of Neoantigen-based Personalized mRNA Therapy iNeo-Vac-R01 Plus PD-1 Inhibitor in Adjuvant Treatment of Liver Cancer Post Radical Resection | recruiting | Phase 1 / Phase 2 | 20 | Yinghua XuOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05024214 | Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors | recruiting | Phase 1 / Phase 2 | 170 | 3D Medicines (Sichuan) Co., Ltd.INDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT05427487 | Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours | recruiting | Phase 1 | 70 | ImmVirx Pty LtdINDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT04008797 | A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor | active not recruiting | Phase 1 / Phase 2 | 301 | Eisai Inc.INDUSTRY | 10 | Mar 24, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 27, 2026source: clinicaltrials